このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Clinical Study to Collect Real-wordt Data on Safety and Clinical Performance of the VCFix Spinal System for Treatment of Vertebral Compression Fractures of (Suspected) Osteoporotic Origin. (EXPAND-US)

2026年11月4日 更新者:Amber Implants B.V.

A Prospective, Multicenter, Post-Market Clinical Study Collecting Real-World Data of the VCFix Spinal System in Stand-Alone Configuration for Vertebral Augmentation (EXPAND-US)

This study is designed as a prospective, post-market, multi-center, single-arm study to collect real-world data of the VCFix Spinal System used in US clinical practice.

Approximately 5 centers in the US will enroll subjects with VCF in a non-randomized fashion, and VCFix will be used within its cleared purpose and indications for use.

The study has been designed to be methodologically compatible with the EU EXPAND (CIP-VS02-EU) study, thereby aiming for the pooling of data to the EU study. Data pooling will be pursued only as a sensitivity analysis if pre-specified similarity criteria are met. The US study provides meaningful real-world evidence regardless of pooling feasibility.

The targeted patient population, assessment schedule, and study endpoints are therefore similar to those of the EU EXPAND study.

調査の概要

研究の種類

観察的

入学 (推定)

30

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • New York
      • New York、New York、アメリカ、10467
        • 募集
        • Montefiore Medical Center
        • コンタクト:
          • Research Administrator
          • 電話番号:(718) 920-6202
    • Oklahoma
      • Oklahoma City、Oklahoma、アメリカ、73104
        • まだ募集していません
        • University of Oklahoma Health Campus
        • コンタクト:
          • Research Project Manager
          • 電話番号:(405) 271-8001
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19107
        • まだ募集していません
        • Rothman Orthopaedics
        • コンタクト:
          • Clinical Research Coordinator
          • 電話番号:(484) 335-2910

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

21年~85年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Adult patients undergoing treatment with the VCFix Spinal System as part of standard clinical care for vertebral compression fractures. The study will enroll patients treated according to routine clinical practice and will collect real-world evidence on clinical outcomes, radiographic outcomes, and patient-reported outcomes following treatment.

説明

Inclusion Criteria:

  • 1. Subject is ≥ 21 to ≤ 85 years old. 2.

Single vertebral fracture which meets all of the following criteria:

  • Type A fractures from AO spine classification (compression injuries);
  • Vertebral fracture located in the thoracic and lumbar regions of the spine
  • Fracture age < 6 weeks or fractures with anatomic signs of reducibility (based on radiographic evidence as well as patient history)
  • Vertebral fracture shows an estimated height loss in the anterior or mid third of the vertebral body (VB) of at least 10% but not more than 60% based on radiographic evidence
  • Target VB has appropriate anatomy, i.e. suitable pedicle diameter, pedicle length and chord length that would allow for selection of correct implant size, as described in the IFU and based on axial MRI/CT scan before surgery 3. Subject is diagnosed with, or has a suspected diagnosis of, severe osteoporosis, including low trabecular bone quality , and/or an oversized vertebral body as compared to implant size (e.g. relatively small pedicle requiring smaller implant size than desired for vertebral body size and/or fracture characteristics and location) 4. Subject has a NPRS back pain score of ≥5 5. Subject is a candidate for surgical intervention based on investigator opinion 6. Subject has a body Mass Index (BMI) < 35 7. Subject is mentally capable of complying with trial protocol requirements for the duration of the study 8. Subject can understand the risks and benefits of participating in the study and is able to provide written informed consent

Exclusion Criteria:

  1. Neoplasms with posterior involvement and/or presence of a mass within the spinal canal

  2. Non-mobile fractures (i.e., fracture is not recent (>6 weeks), bone marrow edema or fluid or empty cleft are not visible in radiographic imaging, or fracture mode does not allow for fracture reduction in craniocaudal direction).

  3. Spondylolisthesis > Grade 1 at target vertebral body(s)

  4. Local kyphotic angle > 30°

  5. Any pre-existing vertebral fracture prior to the index fracture

  6. Previous spine surgery, balloon kyphoplasty or vertebroplasty, for any vertebral fracture

  7. Subjects that require anterior stabilization of the index fracture

  8. Fracture to the pedicle based on radiographic evaluation

  9. Spinal cord compression or canal compromise requiring decompression

  10. Severe back pain due to causes other than acute fracture with NPRS score > 5

  11. The subject has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis)

  12. Pain due to any other condition that requires daily narcotic (opiates or opioids) medication

  13. Pre-existing neurological deficit, radiculopathy or myelopathy

  14. Pre-existing condition or significant co-morbidity:

    1. Uncontrolled diabetes (HbA1c >8%)
    2. Severe cardiopulmonary deficiencies
    3. Any other condition that would impact study outcome in the opinion of the investigator
  15. Irreversible coagulopathy or bleeding disorder

  16. Contraindications to both MRI and Computed Tomography (CT) imaging

  17. Concurrent participation in another clinical study which could potentially interfere with the outcome of this study

  18. A life expectancy less than the study duration or undergoing palliative care

  19. Subject non-ambulatory prior to fracture Allergy to any components of the device/instruments used during the procedure

  20. Allergy to any components of the device/instruments used during the procedure

  21. Active or incompletely treated infection of the vertebral column or active systemic infection, including unresolved urinary tract infection

  22. Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfecta, Paget's disease, etc.)

  23. Any evidence of alcohol or drug abuse

  24. Ongoing long-term steroid therapy (steroid dose ≥30 mg /day for >3 months)

  25. The subject is currently on anti-cancer therapy or anti-HIV therapy

  26. Pregnancy or subjects with child-bearing potential that are unwilling to use contraception throughout the study duration.

  27. Patient known to be involved in medical litigation including Workmen's Compensation prior to the surgery

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
介入・治療
Implant of the VCFix device per IFU

Patients with a (suspected) diagnosis of severe osteoporosis and a single vertebral compression fracture

The distinguishing features of this inetrvention reside in: 1. In situ adjustment and maintenance of the height and angle of the device that allows expansion of the fractured VB in the cranio-caudal direction to realign the vertebral endplates and correct kyphosis. 2. The complex titanium perforated structure with optimized surface roughness that allows possible bone attachment, thereby permitting natural healing of the bone and potentially providing more stability to the device and the treated vertebra over time. 3. The ability to connect the posterior to the anterior column of the spine through the pedicle screw component of the VCFix implant, therefore improving the biomechanical load distribution and consequently the ability to stabilize more severe fractures.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of serious adverse events (SAEs) related to the device and/or investigational procedure (safety)
時間枠:1 month

Incidence of serious adverse events (SAEs) related to the device and/or investigational procedure within 30 days post-procedure. This includes SAEs resulting from mechanical malfunction, structural compromise, device failure, or loss of intended function, as well as events representing deviations from the device's intended medical purpose.

1 month
Vertebral fracture-related pain as assessed by the Numeric Pain Rating Scale (NPRS)
時間枠:6 months

Difference in vertebral fracture-related pain from baseline 6 months post procedure measured by the 11-point (0 = no pain, 10 is worst pain) Numerical Pain Rating Scale (NPRS).

6 months
Functional disability, measured by the Oswestry disability index (ODI)
時間枠:6 months

Difference in functional disability, measured by the Oswestry disability index (ODI) (0-100 scale, where 0 is no disability and 100 is bed bound), from baseline to 6 months post procedure.

6 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Vertebral height difference (anterior, midline, and posterior aspects)
時間枠:Post-Operative, 1Month FU, 6 Months FU, 12 Months FU

Vertebral height difference (anterior, midline, and posterior aspects) at PO (Post-OP), 1M FU, 6M FU and 12M FU as compared to baseline.

Post-Operative, 1Month FU, 6 Months FU, 12 Months FU
Kyphotic angle and Cobb angle improvement at Post-Operative, 1 Month FU, 6 Months FU and 12 Months FU.
時間枠:Post-Operative, 1 Month FU, 6 Months FU and 12 Months FU.

Kyphotic angle and Cobb angle improvement

Post-Operative, 1 Month FU, 6 Months FU and 12 Months FU.
Vertebral fracture-related pain as assessed by the Numeric Pain Rating Scale (NPRS)
時間枠:Discharge, 1, 3, 6 and 12 Months FU compared to baseline.

Difference in vertebral fracture-related pain from baseline to Discharge, 1, 3, 6 and 12 Months post procedure measured by the 11-point (0 = no pain, 10 is worst pain) Numerical Pain Rating Scale (NPRS).

Discharge, 1, 3, 6 and 12 Months FU compared to baseline.
Functional disability, measured by the Oswestry disability index (ODI)
時間枠:Discharge, 1, 3, 6 and 12 months FU

Improvement in function (measured by the 100-point Oswestry Disability Index (ODI)) at discharge, 1, 3, 6 and 12 months FU compared to baseline.

Discharge, 1, 3, 6 and 12 months FU
Health-related quality of life (HRQoL) measured by EuroQol 5-Dimension Scale (EQ-5D-5L) at 1 Month, 3 Months, 6 Months and 12 Months post-procedure compared to baseline
時間枠:1 Month, 3 Months, 6 Months and 12 Months post-procedure compared to baseline

Improvement of Health-related quality of life (HRQoL)

1 Month, 3 Months, 6 Months and 12 Months post-procedure compared to baseline
Device-related serious adverse events assessed at 12- and 24- months post-procedure.
時間枠:12 months FU, 24 months FU

Device-related serious adverse events

12 months FU, 24 months FU
All (per protocol reportable) adverse events assessed at 12- and 24- months post-procedure.
時間枠:12 Months FU, 24 Months FU

All (per protocol reportable) adverse events assessed at 12- and 24- months post-procedure.

12 Months FU, 24 Months FU

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年10月4日

一次修了 (推定)

2027年7月21日

研究の完了 (推定)

2028年12月31日

試験登録日

最初に提出

2026年7月31日

QC基準を満たした最初の提出物

2026年11月4日

最初の投稿 (実際)

2026年11月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月5日

QC基準を満たした最後の更新が送信されました

2026年11月4日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する